Recent advances in the management of renal cell carcinoma

F1000Research

Volumn 5, Issue , 2016, Pages

  Molina, Ana M ^a   Nanus, David M ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AXITINIB; BEVACIZUMAB; CABOZANTINIB; EVEROLIMUS; NIVOLUMAB; PAZOPANIB; SUNITINIB; VASCULOTROPIN INHIBITOR;

CANCER CHEMOTHERAPY; CANCER SURVIVAL; CANCER THERAPY; DRUG APPROVAL; DRUG EFFICACY; DRUG SAFETY; FOOD AND DRUG ADMINISTRATION; HUMAN; KIDNEY CARCINOMA; KIDNEY METASTASIS; OUTCOME ASSESSMENT; PATIENT CARE; PHASE 3 CLINICAL TRIAL (TOPIC); PROTEIN TARGETING; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW;

EID: 84964661207     PISSN: 20461402     EISSN: 1759796X     Source Type: Journal    
DOI: 10.12688/f1000research.7935.1     Document Type: Review

References (19)

1. Siegel RL Miller KD Jemal A: Cancer statistics, 2016. CA Cancer J Clin. 2016;66(1):7-30. 26742998 10.3322/caac.21332
2. Fyfe G Fisher RI Rosenberg SA: Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J Clin Oncol. 1995;13(3):688-96. 7884429
3. Fisher RI Rosenberg SA Fyfe G: Long-term survival update for high-dose recombinant interleukin-2 in patients with renal cell carcinoma. Cancer J Sci Am. 2000;6(Suppl 1):S55-7. 10685660
4. McDermott DF: Update on the application of interleukin-2 in the treatment of renal cell carcinoma. Clin Cancer Res. 2007;13(2 Pt 2):716s-720s. 17255299 10.1158/1078-0432.CCR-06-1872
5. Ljungberg B Bensalah K Canfield S: EAU guidelines on renal cell carcinoma: 2014 update. Eur Urol. 2015;67(5):913-24. 25616710 10.1016/j.eururo.2015.01.005
6. Motzer RJ Escudier B Oudard S: Phase 3 trial of everolimus for metastatic renal cell carcinoma: Final results and analysis of prognostic factors. Cancer. 2010;116(18):4256-65. 20549832 10.1002/cncr.25219 F1000 Recommendation
7. Motzer RJ Hutson TE Cella D: Pazopanib versus sunitinib in metastatic renal-cell carcinoma. N Engl J Med. 2013;369(8):722-31. 23964934 10.1056/NEJMoa1303989 F1000 Recommendation
8. Escudier B Pluzanska A Koralewski P: Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet. 2007;370(9605):2103-11. 18156031 10.1016/S0140-6736(07)61904-7 F1000 Recommendation
9. Rini BI Halabi S Rosenberg JE: Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206. J Clin Oncol. 2010;28(13):2137-43. 20368558 10.1200/JCO.2009.26.5561 2860433 F1000 Recommendation
10. Rini BI Escudier B Tomczak P: Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet. 2011;378(9807):1931-9. 22056247 10.1016/S0140-6736(11)61613-9 F1000 Recommendation
11. Choueiri TK Escudier B Powles T: Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma. N Engl J Med. 2015;373(19):1814-23. 26406150 10.1056/NEJMoa1510016 F1000 Recommendation
12. Choueiri TK Pal SK McDermott DF: A phase I study of cabozantinib (XL184) in patients with renal cell cancer. Ann Oncol. 2014;25(8):1603-8. 24827131 10.1093/annonc/mdu184 F1000 Recommendation
13. Escudier B Motzer RJ Powles T: Subgroup analyses of METEOR, a randomized phase 3 trial of cabozantinib versus everolimus in patients (pts) with advanced renal cell carcinoma (RCC). J Clin Oncol. 2016;34(suppl 2S; abstr 499). Reference Source
14. Kline J Gajewski TF: Clinical development of mAbs to block the PD1 pathway as an immunotherapy for cancer. Curr Opin Investig Drugs. 2010;11(12):1354-9. 21154117 F1000 Recommendation
15. Thompson RH Dong H Lohse CM: PD-1 is expressed by tumor-infiltrating immune cells and is associated with poor outcome for patients with renal cell carcinoma. Clin Cancer Res. 2007;13(6):1757-61. 17363529 10.1158/1078-0432.CCR-06-2599 F1000 Recommendation
16. Topalian SL Hodi FS Brahmer JR: Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;366(26):2443-54. 22658127 10.1056/NEJMoa1200690 3544539 F1000 Recommendation
17. Motzer RJ Rini BI McDermott DF: Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial. J Clin Oncol. 2015;33(13):1430-7. 25452452 10.1200/JCO.2014.59.0703 F1000 Recommendation
18. Motzer RJ Escudier B McDermott DF: Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. N Engl J Med. 2015;373(19):1803-13. 26406148 10.1056/NEJMoa1510665 F1000 Recommendation
19. Motzer RJ Sharma P McDermott DF: CheckMate 025 phase III trial: Outcomes by key baseline factors and prior therapy for nivolumab (NIVO) versus everolimus (EVE) in advanced renal cell carcinoma (RCC). J Clin Oncol. 2016;34(suppl 2S; abstr 498). Reference Source